Related Experiment Video
Updated: Jan 25, 2026

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
Published on: July 12, 2024
Prognosis and Risk Stratification of Patients With Advanced Heart Failure (from PROBE)
Matteo Cameli1, Maria Concetta Pastore1, Giulia E Mandoli1
1Department of Cardiovascular Diseases, University of Siena, Siena, Italy.
Insights
A new echocardiographic score, the PROBE score, accurately predicts major adverse cardiac events in advanced chronic heart failure (CHF) patients. This tool aids in noninvasive, individualized prognosis and risk stratification for better patient management.
Area of Science:
- Cardiology
- Echocardiography
- Heart Failure Research
Background:
- Advanced chronic heart failure (CHF) lacks comprehensive prognostic scores utilizing echocardiographic data.
- Existing scores often do not integrate first- and second-level echocardiographic indices for advanced CHF patients.
Purpose of the Study:
- To develop and validate a novel prognostic echocardiographic score for patients with advanced CHF.
- To identify key echocardiographic predictors of major adverse cardiac events (MACE) in this population.
Main Methods:
- Prospective analysis of 110 advanced CHF patients using standard, 3D, and speckle tracking echocardiography.
- Identification of MACE predictors via ROC analysis (AUC >0.70).
- Development of the Prognostic Right heart and Atrial index (PROBE) score and validation using Kaplan-Meier analysis.
Main Results:
- Key predictors identified: left atrial volume index, right ventricular sphericity index, right ventricular fractional area change, and free-wall right ventricular longitudinal strain.
- The PROBE score demonstrated high predictive accuracy (AUC = 0.90) for MACE.
- Patients were stratified into low, intermediate, and high-risk groups with significant differences in event-free survival.
Conclusions:
- The PROBE score, incorporating echocardiographic parameters, effectively predicts MACE in advanced CHF.
- This score offers a valuable, noninvasive tool for individualized prognosis and risk stratification in advanced CHF.
- The PROBE score enhances clinical decision-making for patients with advanced chronic heart failure.
Abstract:
In recent years, many prognostic scores have been developed for advanced chronic heart failure (CHF), but none of them is comprised of first- and second level echocardiographic indexes. The aim was to create a new prognostic echocardiographic score for patients with advanced CHF. Patients with advanced CHF were analyzed by standard, 3D, and speckle tracking echocardiography and followed prospectively for 2 ± 0.7 years recording major adverse cardiac events (MACE): cardiovascular death, hospitalization for HF, emergency heart transplantation, and left ventricular assist device or intra-aortic balloon pump implantation. A total of 110 patients were enrolled. The best predictors of MACE were selected on the basis of area under the curve by receiver operating characteristic analysis >0.70: left atrial volume index (no MACE vs MACE groups, 51.3 ± 20 ml/m2 vs 67 ± 20 ml/m2, p = 0.0003), right ventricular sphericity index (0.53 ± 0.09 vs 0.61 ± 0.10, p = 0.0002), right ventricular fractional area change (41 ± 9% vs 33 ± 9.5, p <0.0001), free-wall right ventricular longitudinal strain (-20 ± 4.5% vs -16 ± 6%, p = 0.0013). A prognostic score formula was calculated as: PROBE score = 1(if left atrial volume index >65 ml/m2) + 1(if right ventricular sphericity index >0.53) + 0.5(if right ventricular fractional area change <36.5%) + 1(if free-wall right ventricular longitudinal strain >-14%). It presented an area under the curve by receiver operating characteristic analysis of 0.90 and classified patients at low (PROBE ≤1), intermediate (PROBE = 1 to 2), or high (PROBE >2) risk of MACE. The Kaplan-Meier analysis revealed a strong correlation between the event-free survival rate and the 3 groups. In conclusion, the PROBE score, with first- and second level echocardiographic parameters, demonstrated a good predictive value for MACE. It represents a useful tool for a noninvasive, individualized, and accurate evaluation and stratification of prognosis in patients with advanced CHF.
More Related Videos
04:05Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
Published on: June 30, 2023
04:20Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure
Published on: October 1, 2019
Related Concept Videos
Heart Failure II: Pathophysiology
Pathophysiology of Heart Failure
Heart Failure I: Introduction
Heart Failure VI: Adjunct Therapies
Heart Failure Drugs: Diuretics
Heart Failure V: Medical Management